A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation Meeting Abstract
| Authors: | Mato, A.; Tang, B.; Azmi, S.; Yang, K. R.; Stern, J. C.; Hedrick, E.; Huang, J.; Sharman, J. P. |
| Abstract Title: | A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-01 |
| Language: | English |
| ACCESSION: | WOS:000607547205197 |
| DOI: | 10.1182/blood-2020-134119 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1 -- Source: Wos |
